PsyPost on MSN1h
Your brain’s secret painkiller: Can you switch it on?
In the second world war, the physician Henry Beecher observed that some of his soldier patients, despite being injured on the ...
openaccessgovernment2d
Conflicting guidance when providing care for chronic pain – creating a Recommendation Map
Dr. Jason Busse and I are pleased to present a project at McMaster on the safe and effective use of opioids for chronic pain ...
Investing4d
FDA approves Vertex's first-in-class non-opioid analgesic for acute pain
Journavx works by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, which intercepts pain signals before they reach the brain. This approval marks the ...
Click2Houston4d
Doctors at NexGenEsis Healthcare say they are revolutionizing pain relief with regenerative medicine
Dr. Abhishek Reddy and Dr. Joe Fuhrman stop by Houston Life to discuss their innovative approach to pain management.
AFP5d
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
“I believe JOURNAVX could redefine the management of pain and become a foundational treatment option for people with all types of moderate-to-severe acute pain, where options aside from opioids ...
BioSpace6d
Vertex’s Journavx Changes the Pain Treatment Landscape But Opioids Here to Stay
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...
WRIC6d
FDA approves first opioid-free painkiller in over two decades
The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to ...
Vertex Pharmaceuticals Incorporated (VRTX): Among Renaissance Technologies Portfolio’s Top Stock Picks
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
Facebook | The Stute9d
FDA approves first-of-its-kind non-opioid pain medication
On January 30, 2025, the US FDA approved Journavx (suzetrigine) 50mg oral tablets to use in the treatment of moderate to severe acute pain, making it the first non-opioid analgesic of its class to ...
JD Supra10d
FDA Approved Journavx, a Non-Opioid Drug for Pain Management
On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...